RTX is benefiting from rising global defense spending, attracting defense ETF inflows, and solidifying its position as a patent leader; its Ray Therapeutics arm also secured PRIME designation for a retinal drug, boosting growth prospects.
Street
Buy
Target $224.89 • +30% • 26 analysts
VCP DCF
fair
-13% • FV $151.54
Peers
Fair
-3% • 87/100 confidence
VCP Est.
FY+1 Rev +7%
Base target $234.39 • 66/100 confidence
Defense ETFs to Buy as Global Military Spending Rises 2.9%
zacks.com • 2026-04-29 11:46













